☆ 3.8 Article

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

CANCER RESEARCH COMMUNICATIONS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Amit G. Singal et al.

HEPATOLOGY (2023)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma

Katherine A. McGlynn et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a major global health concern. While HBV and HCV remain important risk factors for HCC, efforts in vaccination and treatment are showing promise. However, the increasing prevalence of metabolic risk factors like obesity and diabetes, as well as other factors like excessive alcohol consumption, present ongoing challenges in the prevention of liver cancer.

HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

May Tun Saung et al.

Summary: The FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of HCC based on data from cohort 4 of Check-Mate 040, showing comparable BICR-assessed ORR in all three arms at 31%-32%. Adverse events were consistent with known profiles of nivolumab and ipilimumab, with no new safety events identified.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Sandra J. Casak et al.

Summary: The FDA approved atezolizumab in combination with bevacizumab for the treatment of unresectable hepatocellular carcinoma. The approval was based on Study IMbrave150 which showed improved overall survival and progression-free survival compared to standard care with sorafenib. Adverse reactions included hypertension, fatigue, and proteinuria.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Anita Gul et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Hashem O. Alsaab et al.

FRONTIERS IN PHARMACOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Joong-Won Park et al.

LIVER INTERNATIONAL (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Immunology

Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo

Rituparna Das et al.

JOURNAL OF IMMUNOLOGY (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson

L. Fournier et al.

DIAGNOSTIC AND INTERVENTIONAL IMAGING (2014)

添加到收藏夹

Article Oncology

PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

Feng Shi et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.